Quote | Inozyme Pharma Inc. (NASDAQ:INZY)
Last: | $4.49 |
---|---|
Change Percent: | 0.0% |
Open: | $4.46 |
Close: | $4.49 |
High: | $4.55 |
Low: | $4.43 |
Volume: | 197,852 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Inozyme Pharma Inc. (NASDAQ:INZY)
2024-07-02 13:43:54 ET More on Inozyme Pharma Seeking Alpha’s Quant Rating on Inozyme Pharma Historical earnings data for Inozyme Pharma Financial information for Inozyme Pharma Read the full article on Seeking Alpha For further details see: ...
BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
Message Board Posts | Inozyme Pharma Inc. (NASDAQ:INZY)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $INZY 22% v2,6M c5.73 f43,720M H5.95 ML.2.51 RL4.51 gapNgo | znewcar1 | investorshangout | 04/01/2023 3:27:00 AM |
Loading | INFINITI | investorshub | 02/17/2023 1:19:27 PM |
Have a feeling this about to squeeze into | Jess070283 | investorshub | 02/16/2023 3:10:59 PM |
Great week so far. Gotta keep | tj9938 | investorshub | 01/06/2023 4:00:14 PM |
Quietest board out there | tj9938 | investorshub | 12/30/2022 6:58:51 PM |
News, Short Squeeze, Breakout and More Instantly...
BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferatio...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation...